Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to -$19.5 million.

  • Cartesian Therapeutics' Net Income towards Common Stockholders fell 3010.27% to -$19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$50.4 million, marking a year-over-year increase of 7646.72%. This contributed to the annual value of -$77.4 million for FY2024, which is 6476.08% up from last year.
  • Per Cartesian Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$19.5 million for Q3 2025, which was down 3010.27% from $13.3 million recorded in Q2 2025.
  • Over the past 5 years, Cartesian Therapeutics' Net Income towards Common Stockholders peaked at $13.4 million during Q2 2022, and registered a low of -$196.7 million during Q4 2023.
  • For the 5-year period, Cartesian Therapeutics' Net Income towards Common Stockholders averaged around -$15.5 million, with its median value being -$9.0 million (2023).
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first surged by 550566.8% in 2022, then crashed by 343714.58% in 2023.
  • Quarter analysis of 5 years shows Cartesian Therapeutics' Net Income towards Common Stockholders stood at $12.2 million in 2021, then plummeted by 51.85% to $5.9 million in 2022, then plummeted by 3437.15% to -$196.7 million in 2023, then surged by 87.66% to -$24.3 million in 2024, then rose by 19.6% to -$19.5 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$19.5 million for Q3 2025, versus $13.3 million for Q2 2025 and -$19.9 million for Q1 2025.